

1. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
2. (withdrawn) The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 3.
3. (withdrawn) The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 4.
4. (withdrawn) The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 1.
5. (withdrawn) The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 2.
6. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 4.
7. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 3.
8. (original) An isolated polypeptide as set forth in SEQ ID NO: 1.
9. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 2.
10. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 1.
11. (withdrawn) The nucleic acid construct of claim 10, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
12. (withdrawn) The nucleic acid construct of claim 10, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
13. (withdrawn) A host cell comprising the nucleic acid construct of claim 10.

14. (Currently Amended) An isolated polypeptide comprising an amino acid sequence at least 70% 95% identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters ~~or an active portion thereof~~.

15. (withdrawn) An antibody or an antibody fragment being capable of specifically binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

16. (withdrawn) An oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

17. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

18. (withdrawn) A method of treating Met-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters, thereby treating the Met-related disease in a subject.

19. (withdrawn) The method of claim 18, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

20. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

21. (withdrawn) The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 8.

22. (withdrawn) The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 7.

23. (withdrawn) The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 5.

24. (withdrawn) The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 6.

25. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 8.

26. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 7.

27. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 5.

28. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 6.

29. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 20.

30. (withdrawn) The nucleic acid construct of claim 29, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

31. (withdrawn) The nucleic acid construct of claim 29, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

32. (withdrawn) A host cell comprising the nucleic acid construct of claim 29.

33. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet

switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

34. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

35. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

36. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

37. (withdrawn) A method of treating an IL-6-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters, thereby treating the IL-6-related disease in the subject.

38. (withdrawn) The Method of claim 37, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

39. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

40. (withdrawn) The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 11.

41. (withdrawn) The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 12.

42. (withdrawn) The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 9.

43. (withdrawn) The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 10.

44. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 11.

45. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 12.

46. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 10.

47. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 9.

48. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 39.

49. (withdrawn) The nucleic acid construct of claim 48, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

50. (withdrawn) The nucleic acid construct of claim 48, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

51. (withdrawn) A host cell comprising the nucleic acid construct of claim 48.

52. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

53. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

54. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

55. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

56. (withdrawn) A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

57. (withdrawn) The method of claim 56, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

58. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

59. (withdrawn) The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 15.

60. (withdrawn) The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 16.

61. (withdrawn) The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 13.

62. (withdrawn) The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 14.

63. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 15.

64. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 16.

65. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 13.

66. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 14.

67. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 58.

68. (withdrawn) The nucleic acid construct of claim 67, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

69. (withdrawn) The nucleic acid construct of claim 67, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

70. (withdrawn) A host cell comprising the nucleic acid construct of claim 67.

71. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

72. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as

determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

73. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

74. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

75. (withdrawn) A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

76. (withdrawn) The method of claim 75, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

77. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

78. (withdrawn) The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 19.

79. (withdrawn) The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 20.



80. (withdrawn) The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 17.
81. (withdrawn) The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 18.
82. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 19.
83. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 20.
84. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 17.
85. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 18.
86. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 77.
87. (withdrawn) The nucleic acid construct of claim 86, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
88. (withdrawn) The nucleic acid construct of claim 86, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
89. (withdrawn) A host cell comprising the nucleic acid construct of claim 86.
90. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
91. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

92. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

93. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

94. (withdrawn) A method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

95. (withdrawn) The method of claim 94, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

96. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

97. (withdrawn) The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 27.

98. (withdrawn) The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 28.

99. (withdrawn) The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 25.

100. (withdrawn) The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 26.
101. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 27.
102. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 28.
103. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 25.
104. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 26.
105. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 96.
106. (withdrawn) The nucleic acid construct of claim 105, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
107. (withdrawn) The nucleic acid construct of claim 105, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
108. (withdrawn) A host cell comprising the nucleic acid construct of claim 105.
109. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
110. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
111. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

112. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

113. (withdrawn) A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

114. (withdrawn) The method of claim 113, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

115. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

116. (withdrawn) The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 24.

117. (withdrawn) The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 23.

118. (withdrawn) The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 21.

119. (withdrawn) The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 22.

120. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 23.

121. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 24.
122. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 21.
123. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 22.
124. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 115.
125. (withdrawn) The nucleic acid construct of claim 124, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
126. (withdrawn) The nucleic acid construct of claim 124, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
127. (withdrawn) A host cell comprising the nucleic acid construct of claim 124.
128. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
129. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
130. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
131. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland

(<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

132. (withdrawn) A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

133. (withdrawn) The method of claim 132, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

134. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

135. (withdrawn) The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 31.

136. (withdrawn) The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 32.

137. (withdrawn) The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 29.

138. (withdrawn) The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 30.

139. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 31.

140. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 32.

141. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 29.

142. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 30.
143. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 134.
144. (withdrawn) The nucleic acid construct of claim 143, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
145. (withdrawn) The nucleic acid construct of claim 143, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
146. (withdrawn) A host cell comprising the nucleic acid construct of claim 143.
147. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.
148. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
149. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.
150. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

151. (withdrawn) A method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

152. (withdrawn) The method of claim 151, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

153. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

154. (withdrawn) The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 35.

155. (withdrawn) The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 36.

156. (withdrawn) The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 33.

157. (withdrawn) The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 34.

158. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 35.

159. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 36.

160. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 33.

161. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 34.



162. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 153.

163. (withdrawn) The nucleic acid construct of claim 162, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

164. (withdrawn) The nucleic acid construct of claim 162, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

165. (withdrawn) A host cell comprising the nucleic acid construct of claim 162.

166. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

167. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

168. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

169. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

170. (withdrawn) A method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN

software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

171. (withdrawn) The method of claim 170, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

172. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

173. (withdrawn) The isolated polynucleotide of claim 172, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 39.

174. (withdrawn) The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 37.

175. (withdrawn) The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 38.

176. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 39.

177. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 37.

178. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 38.

179. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 172.

180. (withdrawn) The nucleic acid construct of claim 179, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

181. (withdrawn) The nucleic acid construct of claim 179, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

182. (withdrawn) A host cell comprising the nucleic acid construct of claim 179.

183. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

184. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

185. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

186. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

187. (withdrawn) A method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

188. (withdrawn) The method of claim 187, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

189. (withdrawn) An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

190. (withdrawn) The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 43.

191. (withdrawn) The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 40.

192. (withdrawn) The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 41.

193. (withdrawn) The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 42.

194. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 43.

195. (withdrawn) An isolated polynucleotide as set forth in SEQ ID NO: 40.

196. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 41.

197. (withdrawn) An isolated polypeptide as set forth in SEQ ID NO: 42.

198. (withdrawn) A nucleic acid construct comprising the isolated polynucleotide of claim 189.

199. (withdrawn) The nucleic acid construct of claim 189, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

200. (withdrawn) The nucleic acid construct of claim 189, further comprising a positive and a negative selection markers for selecting for homologous recombination events.

201. (withdrawn) A host cell comprising the nucleic acid construct of claim 198.

202. (withdrawn) An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters or an active portion thereof.

203. (withdrawn) An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

204. (withdrawn) An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

205. (withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters and a pharmaceutically acceptable carrier or diluent.

206. (withdrawn) A method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the LALIGN software of EMBnet switzerland (<http://www.ch.embnet.org/index.html>) using default parameters.

207. (withdrawn) The method of claim 206, wherein said upregulating expression of said polypeptide is effected by:

- (i) administering said polypeptide to the subject; and/or
- (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

208. (New) A polynucleotide coding for the polypeptide of claim 8.

209. (New) A polynucleotide coding for the polypeptide of claim 14.